tiprankstipranks
Trending News
More News >
Sequent Scientific Limited (IN:SEQUENT)
:SEQUENT
India Market
Advertisement

Sequent Scientific Limited (SEQUENT) AI Stock Analysis

Compare
1 Followers

Top Page

IN:SEQUENT

Sequent Scientific Limited

(SEQUENT)

Rating:54Neutral
Price Target:
₹180.00
▼(-1.91% Downside)
Sequent Scientific Limited's overall stock score is primarily influenced by its financial performance, which shows a recovery in profitability and cash flow management. However, the high P/E ratio suggests overvaluation, and technical indicators point to neutral market sentiment. The absence of earnings call insights and corporate events limits additional context.

Sequent Scientific Limited (SEQUENT) vs. iShares MSCI India ETF (INDA)

Sequent Scientific Limited Business Overview & Revenue Model

Company DescriptionSequent Scientific Limited (SEQUENT) is a leading integrated pharmaceutical company that operates primarily in the animal health sector. With a strong presence in over 100 countries, the company specializes in manufacturing and marketing a wide range of veterinary pharmaceutical products. Sequent's core offerings include active pharmaceutical ingredients (APIs), formulations, and analytical services, catering to both livestock and companion animals. The company is committed to innovation, high-quality standards, and sustainable practices in the animal health industry.
How the Company Makes MoneySequent Scientific Limited generates revenue through multiple streams, primarily from the sale of veterinary pharmaceutical products. The company's revenue model is anchored in manufacturing and distributing active pharmaceutical ingredients (APIs) and formulations to both domestic and international markets. Additionally, Sequent offers analytical services which contribute to its earnings. The company benefits from strategic partnerships, extensive distribution networks, and a strong focus on research and development, which help in expanding its product portfolio and market reach. By leveraging its integrated operations and global presence, Sequent sustains a steady flow of income and enhances its market competitiveness.

Sequent Scientific Limited Financial Statement Overview

Summary
Sequent Scientific Limited has demonstrated a substantial recovery in profitability with improved net income and gross profit margins. However, modest revenue growth and stable leverage ratios indicate a need for strategic expansion and careful debt management.
Income Statement
65
Positive
Sequent Scientific Limited showed a strong recovery in net income from a loss of 358.69 million to a profit of 218.8 million in the latest year, demonstrating significant improvement in profitability. The gross profit margin improved to 47.7% in 2025, a notable increase from 40.5% in 2024. However, the revenue growth rate from 2024 to 2025 was modest at 13.5%, and the EBIT margin was strong at 29.5% in 2025. This indicates a return to operational profitability but highlights slower revenue expansion.
Balance Sheet
60
Neutral
The company's debt-to-equity ratio remained stable around 0.68, reflecting moderate leverage. The return on equity (ROE) improved to 3.1% from a negative ROE in the previous year, showing a turnaround in profitability. The equity ratio was 44.0%, suggesting a balanced capital structure. However, the increase in total debt over the past years may pose potential risks if not managed carefully.
Cash Flow
58
Neutral
The operating cash flow to net income ratio improved significantly, reflecting improved cash generation relative to profitability. Free cash flow saw a significant rise from negative in 2024 to 442.7 million in 2025, indicating better cash management. However, the free cash flow growth rate is not reliable due to prior negative figures, and consistent positive free cash flow will be essential for financial health.
BreakdownTTMDec 2025Dec 2023Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue15.51B15.51B14.18B13.66B14.10B13.52B
Gross Profit7.40B7.40B1.59B5.53B5.66B6.15B
EBITDA1.70B1.59B-464.48M549.80M1.18B2.06B
Net Income218.80M218.80M-1.21B-358.69M409.55M954.42M
Balance Sheet
Total Assets16.02B16.02B15.29B15.40B14.51B13.93B
Cash, Cash Equivalents and Short-Term Investments691.40M691.40M416.25M687.85M591.21M597.03M
Total Debt4.81B4.81B4.44B4.88B3.65B2.77B
Total Liabilities8.32B8.32B7.80B8.27B7.11B6.16B
Stockholders Equity7.04B7.04B6.99B6.57B6.92B7.28B
Cash Flow
Free Cash Flow0.00442.70M-693.71M-2.12M-18.69M619.24M
Operating Cash Flow0.00833.60M168.08M305.95M305.95M1.15B
Investing Cash Flow0.00-247.80M-649.58M-119.05M-955.66M96.48M
Financing Cash Flow0.00-607.30M322.28M45.46M672.57M-1.39B

Sequent Scientific Limited Technical Analysis

Technical Analysis Sentiment
Positive
Last Price183.50
Price Trends
50DMA
179.73
Positive
100DMA
176.96
Positive
200DMA
172.03
Positive
Market Momentum
MACD
-0.55
Negative
RSI
61.01
Neutral
STOCH
84.67
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SEQUENT, the sentiment is Positive. The current price of 183.5 is above the 20-day moving average (MA) of 174.46, above the 50-day MA of 179.73, and above the 200-day MA of 172.03, indicating a bullish trend. The MACD of -0.55 indicates Negative momentum. The RSI at 61.01 is Neutral, neither overbought nor oversold. The STOCH value of 84.67 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:SEQUENT.

Sequent Scientific Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
73
Outperform
₹37.92B27.71
1.54%5.89%-1.30%
66
Neutral
₹43.29B23.69
0.21%-0.03%21.33%
54
Neutral
₹44.38B149.25
12.33%439.46%
54
Neutral
₹561.75B75.08
0.13%10.99%
51
Neutral
$7.92B-0.43-41.69%2.21%22.29%-1.85%
41
Neutral
₹46.75B
-5.57%23.03%
₹48.22B
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:SEQUENT
Sequent Scientific Limited
183.50
9.85
5.67%
IN:AARTIDRUGS
Aarti Drugs Limited
471.20
-81.14
-14.69%
IN:ADVENZYMES
Advanced Enzyme Technologies Ltd
340.25
-108.29
-24.14%
IN:GLENMARK
Glenmark Pharmaceuticals Limited
2,053.50
353.54
20.80%
IN:SPARC
Sun Pharma Advanced Research Co. Ltd.
145.25
-80.95
-35.79%
IN:SUVEN
Suven Life Sciences Limited
222.80
72.05
47.79%

Sequent Scientific Limited Corporate Events

Sequent Scientific Releases Q2 2025 Financial Results
Aug 9, 2025

Sequent Scientific Limited has published its unaudited standalone and consolidated financial results for the quarter ended June 30, 2025, in two newspapers, The Financial Express and Nava Telangana. This announcement is part of the company’s compliance with regulatory requirements, providing stakeholders with insights into its financial performance for the specified period.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 04, 2025